Blog

  • Merz to Acquire Ulthera for $600M: A Deal That Should Raise Some Eyebrows

    Today we are excited to report that NEA medical device portfolio company Ulthera will be acquired by Merz for up to $600 million in cash in upfront and milestone payments.  This acquisition is the largest in Merz’s history, and positions their combined aesthetics franchise for accelerated growth with a comprehensive portfolio of treatment options. Since NEA’s initial investment in late 2007—when Ulthera had just three full time employees, still resided inside its…

  • Uplifting News for Men

    Treating BPH without impotence, incontinence or inpatient hospital stays You’ve seen the commercials—the guy at the football game climbing the stadium stairs, going back and forth to the bathroom, only to miss the big touchdown. Or how about the one where the guy keeps getting up in the middle of the night to go to the bathroom? Night after night, year after year. More than 75 million men worldwide seek treatment for benign prostatic hyperplasia (BPH)—the non-cancerous…

  • Consumerizing Health Coverage: How a new Silicon Valley company is hitting its Stride

    How many Americans understand their health insurance coverage? According to a recent survey from the Journal of Health Economics, only about 14%. It’s one of the top personal expenditures for Americans each year, but the selection process gets a disproportionately low amount of thought and attention because it’s so confusing! One of the best analogies I can point to is purchasing a new mattress. Try shopping at various stores to find the best combination of price, performance and…

  • A New Generation of Technologies Can Help Transform Healthcare

    Note: this post was originally published as a guest column on 'Building a Smarter Planet' on November 14, 2013   I’ve spent much of my life surrounded by doctors. Literally. Both of my parents are physicians. One of my sisters is a doctor; the other is studying to become one. So it’s no wonder that I was bitten by the medical bug. I, however, gravitated toward the business and company-building side of healthcare, where I have spent my entire career. Today, I…

  • Bullish on Boston: Why Biotech (and More) is Booming

    I spend a lot of time in Boston these days. So do many of my partners. In fact, half of our partnership serves on boards in Boston, and we have about two dozen Boston companies in our active portfolio. This is not a new phenomenon—NEA has always been among the most active VCs in Boston—but today we’re spending more time here than ever before. Why? Because we’re seeing more opportunity here than ever before. This might sound counterintuitive at a time when many in our…